Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JJ.

Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector

Johnson & Johnson provides stability through decades of dividend growth while pivoting to high-margin medical technology to outperform the volatile market.

MarketBeat

5 Dividend Stocks Retirees Are Favoring for Steady Income in 2026

Retirees in 2026 are looking for something simple: predictable income without unnecessary risk. With inflation still pressuring household budgets and bond yields bouncing around, many...

Saving Advice

1 Dividend King to Buy and Hold Through Any Market

In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

I have this thing for pretty picture frames – these are my 8 go-to places to shop for the best ones, whether you're framing photos or art prints

Where to buy frames to elevate your walls and the rest of your home with

Ideal Home

2 Dividend Kings Quietly Beating the Market This Year

These two are the calm outperformers that might have been overlooked.

Barchart

Johnson & Johnson ordered to pay women over talcum powder cancer cases

The healthcare giant immediately announced its intention to appeal the liability verdict and compensatory damages

The Independent UK

Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers

Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance drug discovery and improve workflows.

Fortune

Read news from The Economist, FT, and more,
with one subscription

“Took us totally by surprise – sirloin steak quality for chicken nuggets price”: Jet Guitars JT-350 BKM H and JJ-300 P90 SFG review

These guitars have outlines that you'll recognise, but their meagre price points surely belie the set of specs and level of build quality? Let’s find out

Guitar World

Johnson & Johnson lawsuit explained: Families sue over baby powder cancer claims

Thousands in the UK are suing Johnson & Johnson, alleging that the company's baby powder products concealed cancer risks

Evening Standard

64-Year-Old Blames Johnson & Johnson for Her Ovarian Cancer — Joins 3,000 Suing the Pharma Giant

UK's first talc cancer group claim accuses Johnson & Johnson and Kenvue of failing to warn about asbestos risk — £1 billion suit backed by 3,000 claimants.

International Business Times UK

Thousands in UK take legal action against Johnson & Johnson over alleged talc cancer link

High court claim says company knowingly sold product containing asbestos and ‘concealed’ risk to public

The Guardian - UK

The Real Reason Johnson & Johnson Switched to Corn Starch — Too Late to Save Its Reputation?

Johnson & Johnson's belated shift from talc to corn starch in its baby powders came amid mounting litigation—but can it repair the damage to its reputation?

International Business Times UK

‘When I was a child, everyone used it’: woman blames Johnson & Johnson talc for her cancer

Sue Rizzello is among thousands in UK suing the firm, which denies selling baby powder containing asbestos

The Guardian - UK

Johnson & Johnson Reportedly Faces Major UK Lawsuit Over Baby Powder Cancer Risks

A legal claim involving 3,000 people has been reportedly filed against Johnson Johnson (NYSE:JNJ) in the U.K., alleging that the company knowingly sold asbestos-contaminated baby powder.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Johnson & Johnson faces UK lawsuit over cancer claims

IN FULL

The Independent UK

Thousands sue Johnson & Johnson in UK over baby powder cancer claims

The pharmaceutical company has been accused of ‘concealing’ the risk to the public for decades

Barchart

5 Dividend Kings For Generations Of Passive Income

These are five Dividend Kings, companies with 50+ years of dividend increases, covering recent developments, dividend safety, and valuation, so you can identify candidates for durable income that fit your goals.

Fortune

AI came from tech, but the most advanced AI businesses are in every industry

Fortune’s AIQ 50 list of the most “mature” AI companies shows how different businesses are taking advantage of AI to meet their needs.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Why This Dividend King Still Stands Tall

With a strong product portfolio and growth prospects in innovative medicines, this dividend stock is likely to maintain its 63-year streak of dividend increases.

Axios

Tylenol maker Kenvue blasts Trump administration's autism claim

The over-the-counter drug is a critical product for Kenvue.

Benzinga

Johnson & Johnson Showcases Positive AFib Data, Treatment Results

Johnson Johnson (NYSE:JNJ) reported new cardiovascular data at the 2025 European Society of Cardiology Congress.

Barchart

These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

Benzinga

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

Guitar World

“Impressive value for guitarists seeking rich clean/overdrive tones and timeless distortion tones”: PRS Archon Classic Head review

The PRS Archon Classic runs the gamut from crystal cleans to classic crunch and hot-rodded high gain

Barchart

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.